FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:335-347 January 25, 2007 Number 4 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by De Pauw, B. E. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article

ABSTRACT

Background Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation.

Methods In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy. The primary end point was the incidence of proven or probable invasive fungal infections from randomization to day 112 of the fixed treatment period of the study.

Results Of a total of 600 patients, 301 were assigned to posaconazole and 299 to fluconazole. At the end of the fixed 112-day treatment period, posaconazole was found to be as effective as fluconazole in preventing all invasive fungal infections (incidence, 5.3% and 9.0%, respectively; odds ratio, 0.56; 95 percent confidence interval [CI], 0.30 to 1.07; P=0.07) and was superior to fluconazole in preventing proven or probable invasive aspergillosis (2.3% vs. 7.0%; odds ratio, 0.31; 95% CI, 0.13 to 0.75; P=0.006). While patients were receiving study medications (exposure period), in the posaconazole group, as compared with the fluconazole group, there were fewer breakthrough invasive fungal infections (2.4% vs. 7.6%, P=0.004), particularly invasive aspergillosis (1.0% vs. 5.9%, P=0.001). Overall mortality was similar in the two groups, but the number of deaths from invasive fungal infections was lower in the posaconazole group (1%, vs. 4% in the fluconazole group; P=0.046). The incidence of treatment-related adverse events was similar in the two groups (36% in the posaconazole group and 38% in the fluconazole group), and the rates of treatment-related serious adverse events were 13% and 10%, respectively.

Conclusions Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD. It was superior in preventing invasive aspergillosis and reducing the rate of deaths related to fungal infections. (ClinicalTrials.gov number, NCT00034645 [ClinicalTrials.gov] .)

Source Information

From the Johannes Gutenberg University, Mainz, Germany (A.J.U.); Princess Margaret Hospital, Toronto (J.H.L.); the Medical College of Wisconsin, Milwaukee (D.H.V.); Harper Hospital, Detroit (P.C.); Emory University, Atlanta (A.L.); University of Nebraska Medical Center, Omaha (S.R.T.); Medical University of Vienna, Vienna (H.G.); Hospital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil (W.M.A.); University of Florida, Gainesville (V.R.); Schering-Plough Research Institute, Kenilworth, NJ (N.B., L.P., H.P.); and Royal Brisbane Hospital, Brisbane, Australia (S.D.).

Address reprint requests to Dr. Ullmann at the Johannes Gutenberg University, III Medizinische Klinik und Poliklinik, Langenbeckstr. 1, 55101 Mainz, Germany, or at ullmann{at}uni-mainz.de.

Full Text of this Article

Related Letters:

Posaconazole Prophylaxis in Hematologic Cancer
Weiler S., Bellmann R., Kontoyiannis D. P., Lewis R. E., Krause D. S., van Nieuwkoop C., van Dissel J. T., Ullmann A. J., Chandrasekar P., Patino H., Cornely O. A., Ullmann A. J., Hardalo C.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:2214-2218, May 24, 2007. Correspondence

This article has been cited by other articles:

• Lebeaux, D., Lanternier, F., Elie, C., Suarez, F., Buzyn, A., Viard, J.-P., Bougnoux, M.-E., Lecuit, M., Jullien, V., Lortholary, O. (2009). Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults. Antimicrob. Agents Chemother. 53: 5224-5229 [Abstract] [Full Text]  
• Mann, P. A., McNicholas, P. M., Chau, A. S., Patel, R., Mendrick, C., Ullmann, A. J., Cornely, O. A., Patino, H., Black, T. A. (2009). Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species. Antimicrob. Agents Chemother. 53: 5026-5034 [Abstract] [Full Text]  
• Krishna, G., Ma, L., Vickery, D., Yu, X., Wu, I., Power, E., Beresford, E., Komjathy, S. (2009). Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 4749-4752 [Abstract] [Full Text]  
• Maschmeyer, G., Neuburger, S., Fritz, L., Bohme, A., Penack, O., Schwerdtfeger, R., Buchheidt, D., Ludwig, W.-D., on behalf of the Infectious Diseases Working Party, (2009). A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 20: 1560-1564 [Abstract] [Full Text]  
• Michallet, M., Ito, J. I. (2009). Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation. JCO 27: 3398-3409 [Abstract] [Full Text]  
• Dodds Ashley, E. S., Varkey, J. B., Krishna, G., Vickery, D., Ma, L., Yu, X., Malavade, D., Goodwin, M., Perfect, J. R., Power, E. (2009). Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 2960-2964 [Abstract] [Full Text]  
• Zarember, K. A., Cruz, A. R., Huang, C.-Y., Gallin, J. I. (2009). Antifungal Activities of Natural and Synthetic Iron Chelators Alone and in Combination with Azole and Polyene Antibiotics against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53: 2654-2656 [Abstract] [Full Text]  
• Thompson, G. R. III, Rinaldi, M. G., Pennick, G., Dorsey, S. A., Patterson, T. F., Lewis, J. S. II (2009). Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience. Antimicrob. Agents Chemother. 53: 2223-2224 [Full Text]  
• Maschmeyer, G. (2009). Prevention of mould infections. J Antimicrob Chemother 63: i27-i30 [Abstract] [Full Text]  
• Segal, B. H. (2009). Aspergillosis. NEJM 360: 1870-1884 [Full Text]  
• Krishna, G., Moton, A., Ma, L., Medlock, M. M., McLeod, J. (2009). Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 958-966 [Abstract] [Full Text]  
• Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
• Hlava, N., Niemann, C. U., Gropper, M. A., Melcher, M. L. (2009). Analytic Reviews: Postoperative Infectious Complications of Abdominal Solid Organ Transplantation. J Intensive Care Med 24: 3-17 [Abstract]  
• Cornely, O. A., Bohme, A., Buchheidt, D., Einsele, H., Heinz, W. J., Karthaus, M., Krause, S. W., Kruger, W., Maschmeyer, G., Penack, O., Ritter, J., Ruhnke, M., Sandherr, M., Sieniawski, M., Vehreschild, J.-J., Wolf, H.-H., Ullmann, A. J. (2009). Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. haematol 94: 113-122 [Abstract] [Full Text]  
• Ruping, M. J. G. T., Albermann, N., Ebinger, F., Burckhardt, I., Beisel, C., Muller, C., Vehreschild, J. J., Kochanek, M., Fatkenheuer, G., Bangard, C., Ullmann, A. J., Herr, W., Kolbe, K., Hallek, M., Cornely, O. A. (2008). Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 62: 1468-1470 [Full Text]  
• Ayari, S., Gastinne, T., Guillaume, T., Chevallier, P. Sr., le Gouill, S., Blin, N., Ma, X. Sr., Brissot, E., Harousseau, j. L., Moreau, P., Moreau, P., Mohty, M. Sr., Delaunay, J. (2008). Posaconazole as Prophylaxis in Immunocompromised Patients: A Single Center Experience. ASH ANNUAL MEETING ABSTRACTS 112: 4841-4841 [Abstract]  
• Pagano, L., Fianchi, L., Caira, M. (2008). Pulmonary aspergillosis in hematologic malignancies: lights and shadows. haematol 93: 1611-1616 [Full Text]  
• Rachwalski, E. J, Wieczorkiewicz, J. T, Scheetz, M. H (2008). Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. The Annals of Pharmacotherapy 42: 1429-1438 [Abstract] [Full Text]  
• Doyle, S. C. (2008). Aspergillosis Prophylaxis and Treatment for Pediatric HSCT Patients: Environmental and Pharmacologic Options. Journal of Pediatric Oncology Nursing 25: 240-246 [Abstract]  
• Spreghini, E., Maida, C. M., Tomassetti, S., Orlando, F., Giannini, D., Milici, M. E., Scalise, G., Barchiesi, F. (2008). Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole. Antimicrob. Agents Chemother. 52: 1929-1933 [Abstract] [Full Text]  
• Lazarus, H. M., Phillips, G. L., Herzig, R. H., Hurd, D. D., Wolff, S. N., Herzig, G. P. (2008). High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later. JCO 26: 2240-2243 [Full Text]  
• Chowdhry, R., Marshall, W. L. (2008). Analytical Reviews: Antifungal Therapies in the Intensive Care Unit. J Intensive Care Med 23: 151-158 [Abstract]  
• Cornely, O. A., Bohme, A., Reichert, D., Reuter, S., Maschmeyer, G., Maertens, J., Buchheidt, D., Paluszewska, M., Arenz, D., Bethe, U., Effelsberg, J., Lovenich, H., Sieniawski, M., Haas, A., Einsele, H., Eimermacher, H., Martino, R., Silling, G., Hahn, M., Wacker, S., Ullmann, A. J., Karthaus, M., on behalf of The Multinational Case Registry of th, (2008). Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 61: 939-946 [Abstract] [Full Text]  
• Spreghini, E., Maida, C. M., Milici, M. E., Scalise, G., Barchiesi, F. (2008). Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B. Antimicrob. Agents Chemother. 52: 513-517 [Abstract] [Full Text]  
• Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2008). Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program. J. Clin. Microbiol. 46: 551-559 [Abstract] [Full Text]  
• Rogers, T. R. (2008). Treatment of zygomycosis: current and new options. J Antimicrob Chemother 61: i35-i40 [Abstract] [Full Text]  
• Robenshtok, E., Gafter-Gvili, A., Goldberg, E., Weinberger, M., Yeshurun, M., Leibovici, L., Paul, M. (2007). Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis. JCO 25: 5471-5489 [Abstract] [Full Text]  
• Bulpa, P., Dive, A., Sibille, Y. (2007). Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 30: 782-800 [Abstract] [Full Text]  
• Weiler, S., Bellmann, R., Kontoyiannis, D. P., Lewis, R. E., Krause, D. S., van Nieuwkoop, C., van Dissel, J. T., Ullmann, A. J., Chandrasekar, P., Patino, H., Cornely, O. A., Ullmann, A. J., Hardalo, C. (2007). Posaconazole Prophylaxis in Hematologic Cancer. NEJM 356: 2214-2218 [Full Text]  
• De Pauw, B. E., Donnelly, J. P. (2007). Prophylaxis and Aspergillosis -- Has the Principle Been Proven?. NEJM 356: 409-411 [Full Text]  
• (2007). Posaconazole Superior to Fluconazole for Preventing Aspergillosis. JWatch Infect. Diseases 2007: 1-1 [Full Text]